SCHEMBL23453704

SCHEMBL23453704

Cc1onc(C(=O)O)c1Nc1cccc(Br)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 7/20 0.48
▸ RAPGEF4 Q8WZA2 1/20 0.48
▸ ERBB2 P04626 2/20 0.45
▸ PIM1 P11309 2/20 0.44
▸ PIM2 Q9P1W9 1/20 0.44
▸ GAA P10253 1/20 0.40
▸ NCOA1 Q15788 1/20 0.40
▸ NCOA3 Q9Y6Q9 1/20 0.40
▸ EPM2A O95278 1/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ PTPN6 P29350 1/20 0.40
▸ PTPN9 P43378 1/20 0.40
▸ DUSP3 P51452 1/20 0.40
▸ PTPN11 Q06124 1/20 0.40
▸ ABCB1 P08183 1/20 0.40
▸ ABCC1 P33527 1/20 0.40
▸ ABCG2 Q9UNQ0 1/20 0.40
▸ MAOB P27338 2/20 0.39
▸ MAOA P21397 1/20 0.39
▸ TDO2 P48775 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23453731 0.83 RAPGEF4 (0.41) RAPGEF4PTPN1LMNARECQL
SCHEMBL23453703 0.77 ALDH1A1 (0.47) DUSP3PTPN11ABCB1ABCC1ABCG2
SCHEMBL23453754 0.76 RAPGEF4 (0.48) EGFRRAPGEF4ERBB2PIM1PIM2
SCHEMBL22609306 0.76 RAPGEF4 (0.48) EGFRRAPGEF4ERBB2PIM1PIM2
SCHEMBL22609268 0.72 DHODH (0.43) ABCG2TDO2LMNA
SCHEMBL22609245 0.70 MAPT (0.45) RAPGEF4LMNA
SCHEMBL4034243 0.69 KMT2A (0.49) GAAABCB1
SCHEMBL22609283 0.69 ALDH1A1 (0.44) GAALMNA
SCHEMBL23453717 0.69 DHODH (0.41) ABCG2
SCHEMBL22609257 0.69 ALDH1A1 (0.44) GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS EGFR 2260/4885RAPGEF4 3637/4885ERBB2 2325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback